Recorded Pharmacist Educational Series: Gene & Cell Therapy Educational Series: Part 2 – In Vivo & Viral-based Gene Therapy
ACPE Activity Number:0204-0000-25-027-H01-P Release Date: April 26, 2025 Expiration Date: April 26, 2027 Activity Type: Knowledge-based CE Credits: 0.25 contact hours Activity Fee: Member – Free / Non-Member – Not Available
Activity Overview
Gene and cell therapies are quickly integrating into pharmacy practice and present unique challenges not encountered with traditional medications in the clinical pharmacy setting. Health-system pharmacies must take an active role in onboarding these therapies including evaluating biosafety precautions along the medication use pathway, assisting with the development of infrastructure to administer and monitor these therapies, and identifying the practical and financial implications of these therapies within the health-system. A foundational understanding of virus biology is necessary to establish safe handling practices and to optimize patient care. This activity will review the viral replication process, common viral vectors for in vivo gene therapy, and FDA-approved therapies. Finally, novel in vivo gene therapies in the development pipeline will be highlighted.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
This activity was planned to meet the educational needs of pharmacists in hospitals and health systems providing care to patients receiving viral vector-based gene therapies.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.
